---
document_datetime: 2025-10-21 09:42:29
document_pages: 11
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/lemtrada-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
document_name: lemtrada-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
version: success
processing_time: 7.5300133
conversion_datetime: 2025-12-24 17:41:46.481105
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Lemtrada

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                     | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|----------------------|---------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| SW/0053              | Post Authorisation Safety Study results - EMEA/H/C/PSR/S/0051 - Variation | 25/04/2025                          | 06/08/2025                                  | Annex II                         | The existing obligation to conduct the PASS cat 1 Non interventional post-authorisation safety study (PASS): In order to investigate the incidence of mortality in patients treated with Lemtrada compared to a relevant patient population, the MAH shall submit the results of a post- authorisation safety study comparing Lemtrada to an adequate control is now fulfilled and can be removed as a condition in Annex IID. The Annex IID is updated accordingly. Please note, that this assessment is without prejudice to the final outcome of the separate procedure |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|                     |                                                                                                                                         |            |            |                 | EMEA/H/C/003718/PSR/S/0050 for the DUS PASS.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|---------------------|-----------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| SW/0052             | Post Authorisation Safety Study results - EMEA/H/C/PSR/S/0050 - Variation                                                               | 25/04/2025 | 06/08/2025 | Annex II        | The existing obligation to conduct the PASS cat 1 Non interventional post-authorisation safety study (PASS): In order to assess compliance with the therapeutic indication and effectiveness of measures to minimise the risk of cardiovascular and cerebrovascular adverse events in close temporal association with Lemtrada infusion and immune- mediated adverse reaction, the MAH shall submit the results of a drug utilisation study is now fulfilled and can be removed as a condition in Annex IID. The Annex IID is updated accordingly. |
| IB/0051             | B.I.a.1.k - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - New storage site of MCB and/or WCB | 15/07/2024 | n/a        |                 |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| IA/0050             | A.6 - Administrative change - Change in ATC Code/ATC Vet Code                                                                           | 10/04/2024 | 13/01/2025 | SmPC            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| IB/0049             | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                          | 04/01/2024 | 13/01/2025 | Annex II and PL |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| N/0046              | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                        | 27/10/2023 | 13/01/2025 | PL              |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| PSUSA/10055 /202209 | Periodic Safety Update EU Single assessment - alemtuzumab                                                                               | 26/04/2023 | 07/07/2023 | SmPC and PL     | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/10055/202209.                                                                                                                                                                                                                                                                                                                                                                                                         |
| IB/0045/G           | This was an application for a group of variations.                                                                                      | 06/04/2023 | n/a        |                 |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |

<div style=\"page-break-after: always\"></div>

|                     | product - Minor changes to an approved test procedure B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure                                                                                                      |            |            |             |                                                                                                                                            |
|---------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|--------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0043             | B.II.f.1.b.5 - Stability of FP - Extension of the shelf life of the finished product - Biological/immunological medicinal product in accordance with an approved stability protocol                                                                                                            | 07/09/2022 | 07/07/2023 | SmPC        |                                                                                                                                            |
| II/0041             | C.I.11.b - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of change(s) which require to be further substantiated by new additional data to be submitted by the MAH where significant assessment is required | 07/07/2022 | n/a        |             |                                                                                                                                            |
| PSUSA/10055 /202109 | Periodic Safety Update EU Single assessment - alemtuzumab                                                                                                                                                                                                                                      | 22/04/2022 | 21/06/2022 | SmPC and PL | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/10055/202109. |
| IAIN/0042           | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                 | 07/06/2022 | 07/07/2023 | SmPC and PL |                                                                                                                                            |
| II/0038             | C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                                                                                              | 13/01/2022 | 21/06/2022 | SmPC and PL |                                                                                                                                            |
| N/0040              | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                               | 22/12/2021 | 21/06/2022 | PL          |                                                                                                                                            |

<div style=\"page-break-after: always\"></div>

| IA/0036             | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                                                                                                                                    | 27/08/2021   | n/a        |                 |                                                                                                                                            |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-----------------|--------------------------------------------------------------------------------------------------------------------------------------------|
| IAIN/0035           | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                   | 02/08/2021   | 21/06/2022 | SmPC and PL     |                                                                                                                                            |
| PSUSA/10055 /202009 | Periodic Safety Update EU Single assessment - alemtuzumab                                                                                                                                                                                                                                                                                                                        | 22/04/2021   | 21/06/2021 | SmPC and PL     | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/10055/202009. |
| IA/0034             | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                                                                                                                                    | 26/04/2021   | 21/06/2022 | Annex II and PL |                                                                                                                                            |
| II/0032             | To update sections 4.4 and 4.8 of the SmPC to amend the existing warning and adverse drug reactions on Epstein-Barr virus (EBV) infections and EBV associated hepatitis, following safety evaluation report (SER). The package leaflet is updated accordingly. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data | 03/09/2020   | 21/06/2021 | SmPC and PL     | Not applicable                                                                                                                             |
| II/0031             | Submission of an update the RMP (version 7.2) incorporating all amendments and additional activities defined in the Article 20 referral procedure (EMEA/H/A-20/1483/C/3718/0028). C.I.11.b - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of                                                | 09/07/2020   | n/a        |                 |                                                                                                                                            |

<div style=\"page-break-after: always\"></div>

|                     | change(s) which require to be further substantiated by new additional data to be submitted by the MAH where significant assessment is required                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |            |            |                       |                                                                                                                                            |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------------|--------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10055 /201909 | Periodic Safety Update EU Single assessment - alemtuzumab                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 30/04/2020 | 03/07/2020 | SmPC and PL           | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/10055/201909. |
| II/0029/G           | This was an application for a group of variations. B.II.d.1.f - Change in the specification parameters and/or limits of the finished product - Deletion of a specification parameter which may have a significant effect on the overall quality of the finished product B.II.d.1.f - Change in the specification parameters and/or limits of the finished product - Deletion of a specification parameter which may have a significant effect on the overall quality of the finished product B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition) B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure | 23/01/2020 | n/a        |                       |                                                                                                                                            |
| A20/0028            | Pursuant to Article 20 of Regulation (EC) No 726/2004, the European Commission requested on 10 April 2019 the opinion of the European Medicines Agency further to new emerging and serious concerns related to fatal cases, cardiovascular adverse events in close temporal association with Lemtrada infusion and immune-mediated diseases.                                                                                                                                                                                                                                                                                                                                                                                           | 14/11/2019 | 16/01/2020 | SmPC, Annex II and PL | Please refer to the assessment report: Lemtrada EMEA/H/A-31/1483/C/3718/0028                                                               |

<div style=\"page-break-after: always\"></div>

|                     | The PRAC was requested to assess the impact thereof on the benefit-risk balance of Lemtrada and to give its recommendation whether the marketing authorisation of this product should be maintained, varied, suspended or revoked.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |            |            |             |                                                                                                                                            |
|---------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|--------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10055 /201809 | Periodic Safety Update EU Single assessment - alemtuzumab                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 26/04/2019 | 29/04/2019 | SmPC and PL | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/10055/201809. |
| IAIN/0026           | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 22/11/2018 | 16/01/2020 | SmPC and PL |                                                                                                                                            |
| II/0025/G           | This was an application for a group of variations. B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place B.II.b.3.c - Change in the manufacturing process of the finished or intermediate product - The product is a biological/immunological medicinal product and the change requires an assessment of comparability B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure B.II.d.2.b - Change in test procedure for the finished product - Deletion of a test procedure if an alternative method is already authorised B.II.d.2.d - Change in test procedure for the finished | 18/10/2018 | n/a        |             |                                                                                                                                            |

<div style=\"page-break-after: always\"></div>

|           | product - Other changes to a test procedure (including replacement or addition) B.II.e.6.b - Change in any part of the (primary) packaging material not in contact with the finished product formulation - Change that does not affect the product information                                                                                                                                                                                                                                                                                                             |            |            |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0023   | Update of section 4.4 of the SmPC to add a new warning on acute acalculous cholecystitis following a cumulative review. The Package Leaflet is updated accordingly. This procedure also included an update of section 4.8 of the SmPC in order to update the table of frequencies of adverse reactions in accordance with the SmPC guideline following a request from the PRAC in procedure EMEA/H/C/PSUSA/00010055/201703. C.I.3.z - Change(s) in the SPC, Labelling or PL intended to implement the outcome of a procedure concerning PSUR or PASS or the outcome of the | 20/09/2018 | 16/01/2020 | SmPC and PL            | LEMTRADA may increase the risk of acute acalculous cholecystitis. In controlled clinical studies, 0.2% of LEMTRADA-treated MS patients developed acute acalculous cholecystitis, compared to 0% of patients treated with INFB-1a. During postmarketing use, additional cases of acute acalculous cholecystitis have been reported in LEMTRADA-treated patients. Symptoms of acute acalculous cholecystitis include abdominal pain, abdominal tenderness, fever, nausea, and vomiting. Acute acalculous cholecystitis is a condition that may be associated with high morbidity and mortality rates if not diagnosed early and treated. If acute acalculous cholecystitis is suspected, evaluate and treat promptly. |
| T/0024    | Transfer of Marketing Authorisation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 17/07/2018 | 23/08/2018 | SmPC, Labelling and PL |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| II/0021/G | This was an application for a group of variations. B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.II.d.1.c - Change in the specification parameters                                                                                                                                                                                                                                                                                                                                 | 19/07/2018 | n/a        |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |

<div style=\"page-break-after: always\"></div>

|                     | and/or limits of the finished product - Addition of a new specification parameter to the specification with its corresponding test method B.II.d.1.f - Change in the specification parameters and/or limits of the finished product - Deletion of a specification parameter which may have a significant effect on the overall quality of the finished product                                                                                           |            |            |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| R/0020              | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                                                                                                                                                  | 26/04/2018 | 02/07/2018 | SmPC, Labelling and PL           | Based on the review of data on quality, safety and efficacy, the CHMP considered that the benefit-risk balance of Lemtrada in the approved indication remains favourable and therefore recommended the renewal of the marketing authorisation with unlimited validity.                                                                                                                                                                                                                                                     |
| IB/0022             | B.II.b.3.z - Change in the manufacturing process of the finished or intermediate product - Other variation                                                                                                                                                                                                                                                                                                                                               | 08/05/2018 | n/a        |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| PSUSA/10055 /201709 | Periodic Safety Update EU Single assessment - alemtuzumab                                                                                                                                                                                                                                                                                                                                                                                                | 12/04/2018 | n/a        |                                  | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| PSUSA/10055 /201703 | Periodic Safety Update EU Single assessment - alemtuzumab                                                                                                                                                                                                                                                                                                                                                                                                | 12/10/2017 | 08/12/2017 | SmPC and PL                      | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/10055/201703.                                                                                                                                                                                                                                                                                                                                                                                 |
| II/0017             | Update of sections 4.2, 4.4, 4.8 and 5.1 of the SmPC in order to update the safety and long term use information in the posology following final results from study CAMMS03409 - An Extension Protocol For Multiple Sclerosis Patients Who Participated in Genzyme-Sponsored Studies of Alemtuzumab (ongoing at the time of the initial MAA) to evaluate the long term safety and efficacy of alemtuzumab in MS patients who received alemtuzumab during | 12/10/2017 | 15/11/2017 | SmPC, Annex II, Labelling and PL | Update of sections 4.2, 4.4, 4.8 and 5.1 of the SmPC in order to update the safety and long term use information in the posology following final results from study CAMMS03409 - An Extension Protocol For Multiple Sclerosis Patients Who Participated in Genzyme-Sponsored Studies of Alemtuzumab (ongoing at the time of the initial MAA) to evaluate the long term safety and efficacy of alemtuzumab in MS patients who received additional treatment courses of alemtuzumab. The update in the posology includes the |

<div style=\"page-break-after: always\"></div>

|                     | previous company-sponsored studies. The RMP version 3.0 has also been submitted. The PL has been updated accordingly. In addition, the Marketing authorisation holder (MAH) took the opportunity to bring the PI in line with the latest QRD template version 10.0 and to introduce editorial corrections in the PI. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data   |            |     | option for a third and fourth treatment course with alemtuzumab if needed. If an additional course is administered, safety-follow up should be continued until 48 months after the last infusion. Updated safety information on immune thrombocytopenic Purpura (ITP), thyroid disorders, infusion-associated reactions and infections has been included.   |
|---------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10055 /201609 | Periodic Safety Update EU Single assessment - alemtuzumab                                                                                                                                                                                                                                                                                                                                                                                | 06/04/2017 | n/a | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                           |
| IB/0016/G           | This was an application for a group of variations. B.I.a.2.z - Changes in the manufacturing process of the AS - Other variation B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure               | 01/03/2017 | n/a |                                                                                                                                                                                                                                                                                                                                                             |
| PSUSA/10055 /201603 | Periodic Safety Update EU Single assessment - alemtuzumab                                                                                                                                                                                                                                                                                                                                                                                | 29/09/2016 | n/a | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                           |

<div style=\"page-break-after: always\"></div>

| II/0014             | Update of the Risk Management Plan to version 2.0 to include Progressive Multifocal Leucoencephalopathy (PML) as important potential risk, to describe the pharmacovigilance activities associated to PML and to include a standarize case definition for the diagnosis of PML. C.I.11.b - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of change(s) which require to be further substantiated by new additional data to be submitted by the MAH where significant assessment is required   | 15/09/2016   | n/a        |             |                                                                                                                                                              |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10055 /201509 | Periodic Safety Update EU Single assessment - alemtuzumab                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 28/04/2016   | 21/06/2016 | SmPC and PL | Please refer to Lemtrada PSUSA-10055-201509 EPAR: Scientific conclusions and grounds recommending the variation to the terms of the marketing authorisation. |
| IB/0012             | B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure                                                                                                                                                                                                                                                                                                                                                                                                                                              | 10/05/2016   | n/a        |             |                                                                                                                                                              |
| PSUSA/10055 /201503 | Periodic Safety Update EU Single assessment - alemtuzumab                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 08/10/2015   | n/a        |             | PRAC Recommendation - maintenance                                                                                                                            |
| II/0010             | B.I.a.2.c - Changes in the manufacturing process of the AS - The change refers to a [-] substance in the manufacture of a biological/immunological substance which may have a significant impact on the medicinal product and is not related to a protocol                                                                                                                                                                                                                                                                                                                       | 24/09/2015   | n/a        |             |                                                                                                                                                              |
| PSUSA/10055         | Periodic Safety Update EU Single assessment -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 10/04/2015   | n/a        |             | PRAC Recommendation - maintenance                                                                                                                            |

<div style=\"page-break-after: always\"></div>

| /201409   | alemtuzumab                                                                                                                                                     |            |            |      |                                   |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------|-----------------------------------|
| PSUV/0005 | Periodic Safety Update                                                                                                                                          | 09/10/2014 | n/a        |      | PRAC Recommendation - maintenance |
| IB/0007   | B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure                                                    | 22/07/2014 | n/a        |      |                                   |
| IB/0006   | B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure                             | 22/07/2014 | n/a        |      |                                   |
| IB/0004   | B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure                             | 28/05/2014 | n/a        |      |                                   |
| IG/0418   | C.I.8.a - Introduction of or changes to a summary of Pharmacovigilance system - Changes in QPPV (including contact details) and/or changes in the PSMF location | 11/04/2014 | n/a        |      |                                   |
| IA/0002   | A.6 - Administrative change - Change in ATC Code/ATC Vet Code                                                                                                   | 17/12/2013 | 15/12/2014 | SmPC |                                   |
| IA/0001   | B.III.1.b.3 - Submission of a new/updated or deletion of Ph. Eur. TSE Certificate of Suitability - Updated certificate from an already approved manufacturer    | 15/11/2013 | n/a        |      |                                   |